top of page

Scientific Advisory Board


Thomas J. Goodwin, PhD, Chief Science & Technology Advisor, is known for his work in physiology and bioengineering research, particularly three-dimensional (3D) tissues for the study of human physiology and tumor biology, 3D models as microbial hosts for infectious disease, and research into the effects of ultra-low frequency electromagnetic fields on human tissues. Dr. Goodwin serves as the Chief Scientific and Technical advisor to GRoK Technologies LLC.

He is the honorary President and Chair of the Personalized Medicine panel of the European Society of Translational Medicine (EUSTM), holds adjunct positions at the University of Texas Medical School, Galveston, Texas, Dept. of Surgery, Division of Cardiothoracic Surgery, the University of Houston, Dept. of Health and Human Performance, and is an Adjunct Scientist at the Texas Biomedical Research Institute and the Southwest National Primate Research Center, which is sponsored by the National Institutes of Health.

Dr. Goodwin has been granted 21 U.S. patents, with several disclosures pending, has published more than 56 peer-reviewed scientific papers, has co-authored two book chapters on 3D biology and human physiology, and is the recipient of more than 70 NASA Scientific and Technical awards. Dr. Goodwin received his Ph.D. in physiology and bioengineering science from the Union Institute and University. He also holds an M.A. in neuroscience from the University of Houston and a B.A. in biology from St. Mary’s University.


Dr. Gorenstein was the Deputy Director and Distinguished Chair of the Institute for Molecular Medicine (IMM) at UT Health Science Center (UT Health) in Houston, Texas and Associate Dean for Research in the School of Medicine. He has also served UT Health as Chair, Department of NanoMedicine and Biomedical Engineering, Deputy Director and James T. Willerson Distinguished Chair, and Director, IMM Center for Proteomics and Systems Biology. 

Dr. Gorenstein was Associate Dean for Research, School of Medicine, the University of Texas Medical Branch at Galveston (UTMB) and the Charles Marc Pomerat Distinguished Professor in the Departments of Biochemistry & Molecular Biology and Neurosciences & Cell Biology. He was the founding Director of the UTMB Sealy Center for Structural Biology and Director of the Gulf Coast Consortium in Magnetic Resonance, a shared facility that includes UTMB, Rice University, Baylor College of Medicine, the University of Houston, UT Health and UT M.D. Anderson Cancer Center.

Dr. Gorenstein has over 40 years' experience in structural biology, drug design, nucleic acid and protein chemistry with over 270 publications. he currently has major translational research programs in proteomics and nanomedicine for both diagnostics and therapeutics, particularly in cancer. dr. Gorenstein also has major programs in next-generation aptamer technologies and NMR structural biology, drug design, nucleic acid and protein chemistry. 

Dr. Gorenstein received a bachelor's degree in chemistry from the Massachusetts Institute of Technology and a master's degree and doctorate in chemistry from Harvard University. Before moving to the Houston/Galveston area, he held faculty positions in the departments of chemistry at the University of Illinois at Chicago and Purdue University. He has received a number of awards, including Guggenheim (to the University of California San Francisco and Senior Fulbright (to Oxford University, England) fellowships and election as fellow to the American Association for the Advancement of Science. Dr. Gorenstein holds over three dozen patents on novel aptamer technology (awarded and pending). Many of which have been licensed to AptaMed and AM Biotechnologies. Galveston and Houston companies he founded.

He currently serves as the Chief Scientific Officer of AM Biotechnologies, Further developing next-generation aptamer and proteomic technologies. 


Mark Shumbera is president of AM Biotechnologies, LLC and serves on its board of managers. He is responsible for formulating and executing company strategy and handles operational responsibilities for the company. In addition, Mr. Shumbera is President of AptaMed Inc., on of the two corporate entities that own majority interest in AM Biotechnologies. Mr. Shumbera was formerly the General Manager (GM) of the commercial development division at MEI Technologies, Inc. (MEIT), a NASA and Department of Defense technical services contractor, where he built and managed MEIT IP assets. Mr. Shumbera has also established and assisted several startup companies.

Mr. Shumbera received a B.S. in Electrical Engineering from Texas A&M University and an MBA from the University of Houston Clear Lake. 

bottom of page